TIMBIE THOMAS E
Known title: DirectorCIK: 0001188309
Associated companies
Transaction History
| TMCI | ▼ Sell | Open Market | 50,000 | $1.2M | 3/15/2023 | View on chart |
| TMCI | ▼ Sell | Gift | 8,300 | $0 | 2/16/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 50,000 | $1.1M | 2/15/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 50,000 | $1.3M | 1/18/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 50,000 | $1.2M | 12/14/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 10,070 | $223K | 11/22/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 224 | $5K | 11/21/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 37,605 | $852K | 11/18/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 2,101 | $49K | 11/18/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 50,000 | $1.0M | 11/16/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 50,000 | $996K | 8/16/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 4,904 | $93K | 8/5/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 48,217 | $895K | 8/4/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 96,879 | $1.8M | 8/3/2022 | View on chart |
| TMCI | ▲ Buy | Grant | 2,295 | $0 | 5/17/2022 | View on chart |
| TMCI | ▼ Sell | Gift | 120,000 | $0 | 5/9/2022 | View on chart |
| TMCI | ▼ Sell | Gift | 95,000 | $0 | 1/13/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 11,171 | $281K | 10/20/2021 | View on chart |
| TMCI | ▼ Sell | Gift | 280,000 | $0 | 9/7/2021 | View on chart |
| TMCI | ▼ Sell | Gift | 280,000 | $0 | 9/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Treace Medical Shares Five-Year Bunion Study Results
Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.
Treace Medical Shares Five-Year Bunion Study Results. Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.